PT  - JOURNAL ARTICLE
AU  - Jaspe, Rossana C
AU  - Sulbaran, Yoneira
AU  - Loureiro, Carmen L
AU  - D’Angelo, Pierina
AU  - Rodríguez, Lieska
AU  - Garzaro, Domingo J
AU  - Rangel, Héctor R
AU  - Pujol, Flor H
TI  - Importance of E484K and N501Y mutations in SARS-CoV-2 for genomic surveillance: rapid detection by restriction enzyme analysis
AID  - 10.1101/2021.05.04.21256650
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.05.04.21256650
4099  - http://medrxiv.org/content/early/2021/05/10/2021.05.04.21256650.short
4100  - http://medrxiv.org/content/early/2021/05/10/2021.05.04.21256650.full
AB  - Introduction Variants of Concern of SARS-CoV-2 (VOCs), the new coronavirus responsible for COVID-19, have emerged in several countries. Two mutations in the gene coding for the Spike protein of the viral genome are particularly important and associated with some of these variants: E484K and N501Y. Restriction enzyme analysis is proposed as a rapid method to detect these two mutations.Methodology A search on GISAID was performed in April 2021 to detect the frequency of these two mutations in the sequence available and their association with other lineages. A small amplicon from the Spike gene was digested with two enzymes: HpyAV, which allows detecting E484K mutation, and MseI, for detecting the N501Y one.Results The mutations E484K and N501Y, associated with VOCs, have emerged in several other lineages, particularly E484K. A 100% correlation was observed with sequencing results.Conclusions The proposed methodology, which allows screening a great number of samples, will probably help to provide more information on the prevalence and epidemiology of these mutations worldwide, to select the candidates for whole-genome sequencing.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by Ministerio del Poder Popular de Ciencia, Tecnologia e Innovacion of Venezuela.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Bioethical Committee of IVIC.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available.